Sam Chun Dang Pharm announced on the 5th that it has exported its ophthalmic disease treatment drug Eylea biosimilar, a copy of a biopharmaceutical, to overseas markets for the first time and will begin sales next month.
A company official noted, "After a lengthy process over the past 10 years involving development, clinical trials, contracts, and obtaining approvals, exports for product sales have finally commenced," and added, "Ninety percent of the shipped volume is in the form of a pre-filled syringe (PFS), which will be the first Eylea biosimilar PFS sold in not only that country but also in the global market."
He continued, "The volume to be exported to that single country in the second half of the year is expected to exceed the annual domestic sales volume of Eylea (approximately 170,000 units), and the export volume for other regions this year has also been confirmed, with product production progressing sequentially."
Sam Chun Dang Pharm expects that its PFS product has competitive advantages over others, allowing its global partners to quickly secure market share from the outset. The acquisition of country-specific approvals for the Eylea biosimilar and the development of high-dose products are also in progress.